Ghrelin - A Possible Opportunity to Improve Appetite

Ghrelin - A Possible Opportunity to Improve Appetite, Nutritional State, Metabolic Integrity and Physical Functioning in Cancer Patients With Progressive Weight Loss

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00681486

Acronym

Phase 3

Enrollment

Registered

2008-05-21

Start date

2003-10-31

Completion date

2008-07-31

Last updated

2009-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Ghrelin, Nutrition, Cancer patients, Survival

Brief summary

The study is designed to evaluate whether ghrelin treatment can improve appetite in weight losing cancer patients.

Detailed description

Randomized study with follow up evaluations each month until preterminal state. Cancer patients will be randomised to either high dose or low dose of active treatment given as daily injection.

Interventions

DRUGGhrelin

High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Weight loss

Exclusion criteria

* Diabetes

Design outcomes

Primary

Measure	Time frame
Food intake	June 2008

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026